Semaglutide News and Research

Latest Semaglutide News and Research

Phase 2 trial reveals Lixisenatide may reduce motor disability in Parkinson’s patients

A trial of lixisenatide to assess its effects in early Parkinson’s disease.

18 Apr 2024

Popular diabetes drugs not linked to thyroid cancer risk, study finds

Treating early-stage heart failure in diabetic patients: Insights from ARISE-HF trial

One of the first studies to attempt to treat early-stage heart failure in patients with Type 2 diabetes did not meet its primary endpoint, but a preplanned subgroup analysis found a statistically significant effect of treatment in patients who were not taking SGLT2 inhibitors or GLP-1 RAs, which are antidiabetic medications that also have benefits for the heart.

8 Apr 2024

Weight loss drugs associated with increased risk of aspiration pneumonia following endoscopy

New research from Cedars-Sinai suggests people who are scheduled for certain medical procedures should stop taking popular weight loss drugs in the days or weeks prior to avoid complications.

27 Mar 2024

AI-based analysis uncovers two plant extracts with potential as GLP-1 agonist weight loss pills

Two plant compounds with potential as GLP-1 agonist weight loss pills have been identified in an AI (artificial intelligence)-based study, the European Congress on Obesity (ECO 2024) (Venice 12-15 May), will hear.

26 Mar 2024

Unlocking weight loss through exercise mimicry with metformin

An "anti-hunger" molecule produced after vigorous exercise is responsible for the moderate weight loss caused by the diabetes medication metformin, according to a new study in mice and humans.

18 Mar 2024

Study offers insight into state Medicaid coverage for anti-obesity drugs

Mounting evidence suggests that FDA-approved weight loss medications, such as Wegovy, not only help patients lose weight but also protect against complications from obesity such as cardiovascular disease.

14 Mar 2024

New research sheds light on how GLP-1 obesity drugs may change food cravings

GLP-1 analog treatments potentially alter food preferences and reduce obesity by decreasing appetite and food consumption, with further research needed for long-term weight maintenance using objective measures.

10 Mar 2024

Diabetes drug dulaglutide may reduce symptoms of depression

The current study highlighted the antidepressant effects of dulaglutide using the CMS depression model. Notably, the potential metabolisms that underlie the antidepressant effect of dulaglutide have been elucidated in this study.

8 Mar 2024

Study reveals mechanisms behind antidepressant effects of diabetes drug

Research in animals has shown that the diabetes drug dulaglutide, which is a glucagon-like peptide-1 (GLP-1) receptor agonist may reduce symptoms of depression.

6 Mar 2024

Study shows semaglutide as a safe and effective therapy for MASLD in people with HIV

A weekly injection of semaglutide was safe and reduced the amount of fat in the liver by 31% in people with HIV and metabolic dysfunction-associated steatotic liver disease (MASLD), according to a presentation today at the 2024 Conference on Retroviruses and Opportunistic Infections (CROI) in Denver.

5 Mar 2024

New hope for binge eating and bulimia: GLP-1 drugs could be the key

GLP-1 receptor agonists show promise in reducing binge eating behaviors in disorders like bulimia nervosa, offering a new avenue for treatment with minimal side effects.

4 Mar 2024

Gut bacteria diversity linked to body weight, athletes show healthier profiles

Systematic review reveals gut microbiome variations correlate with body composition changes across lifespan, highlighting differences between obese individuals and athletes.

29 Feb 2024

Exercise, GLP-1 receptor agonist, or combined approach explored in year-long study

Researchers compare the extent of weight loss after one-year termination of active intervention with GLP-1 receptor agonist, exercise, or combination.

29 Feb 2024

An Arm and a Leg: Wait, is Insulin cheaper now?

Pharmaceutical companies that manufacture insulin made headlines last year when they voluntarily agreed to provide discount cards that lower the monthly cost of insulin for many people to $35.

28 Feb 2024

Bariatric surgery outperforms medical management in long-term diabetes control

People with type 2 diabetes who underwent bariatric surgery achieved much better long-term blood glucose control compared to people who received medical management plus lifestyle interventions, according to a new study published in JAMA, or Journal of the American Medical Association, and funded by the National institute of Diabetes, Digestive and Kidney Diseases, part of The National Institutes of Health.

27 Feb 2024

Underutilized obesity treatments could transform patient health

When someone has obesity, losing even 5% of their body weight can make a major difference in their health -- especially if they can keep from regaining it.

21 Feb 2024

Lactocore Group leverages milk peptides to combat inflammaging

...

From Lactocore Group 21 Feb 2024

AMG 133 (maridebart cafraglutide) weight loss drug shows promise in early trial

AMG 133, an engineered bispecific molecule, demonstrated significant weight loss with a favorable safety profile in a phase 1 clinical trial, offering a promising new treatment option for obesity.

7 Feb 2024

New weight loss drug may be an effective strategy for preventing or treating high blood pressure

The new weight loss medication tirzepatide significantly lowered the systolic blood pressure (the top number in a blood pressure reading) for nearly 500 adults with obesity who took the medication for about eight months, according to new research published today in Hypertension, an American Heart Association journal.

5 Feb 2024